Skip to main content
Larry Tsai, MD, Pulmonology, Boston, MA

Larry W Tsai MD

Critical Care Medicine, Pleural Disease


Instructor in Medicine, Brigham and Women's Hospital

Join to View Full Profile
  • 75 Francis Street Pbb Clinics 3Brigham And Women's Hospital Pulmonary DivisionBoston, MA 02115

  • Phone+1 617-732-5500

Dr. Tsai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Massachusetts General Hospital/BIDMC/Harvard Medical School
    Mass General Brigham/Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2001 - 2003
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
  • Harvard Medical School
    Harvard Medical SchoolClass of 1997

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2000 - 2025
  • MA State Medical License
    MA State Medical License 1999 - 2025
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Critical Care Medicine
    American Board of Internal Medicine Critical Care Medicine
  • Pulmonary Disease
    American Board of Internal Medicine Pulmonary Disease

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia  
    Ivan O Rosas, Ronaldo C Go, Ivor S Douglas, Larry Tsai, Atul Malhotra, The New England Journal of Medicine

Press Mentions

  • Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA™ (Eravacycline) Commercial Opportunity
    Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA™ (Eravacycline) Commercial OpportunityJune 12th, 2019
  • Tetraphase Pharmaceuticals Announces New XERAVA™ (Eravacycline) Data at the 39
    Tetraphase Pharmaceuticals Announces New XERAVA™ (Eravacycline) Data at the 39June 10th, 2019
  • Weekly Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings on Dec 15, 2018
    Weekly Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings on Dec 15, 2018December 15th, 2018
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: